Adecatumumab

Adecatumumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	EpCAM
Clinical data
ATC code	none;
Identifiers
CAS Number	503605-66-1 ;
ChemSpider	none;
UNII	000705ZASD ;
Chemical and physical data
Formula	C6552H10080N1740O2052S46
Molar mass	147533.60 g·mol−1
	(what is this?) (verify)

Last updated November 23, 2025

Adecatumumab (MT201) is a recombinant human IgG1 monoclonal antibody which is used to target tumor cells. It binds to the epithelial cell adhesion molecule (EpCAM - CD326), with the intent to trigger antibody-dependent cellular cytotoxicity. It was developed by Micromet Inc, which was acquired by Amgen.^[1]

Adecatumumab has been used in clinical studies of treatment in colorectal, prostate ^[2] and breast cancers.^[3] Phase II results were published in 2010.^[4]

References

↑ "Adecatumumab - Amgen/Merck Serono". Adis Insight. Springer Nature Switzerland AG.
↑ Oberneder R, Weckermann D, Ebner B, Quadt C, Kirchinger P, Raum T, et al. (October 2006). "A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients". European Journal of Cancer. 42 (15): 2530–8. doi:10.1016/j.ejca.2006.05.029. PMID 16930989.
↑ Prang N, Preithner S, Brischwein K, Göster P, Wöppel A, Müller J, et al. (January 2005). "Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines". British Journal of Cancer. 92 (2): 342–9. doi:10.1038/sj.bjc.6602310. PMC 2361858 . PMID 15655555.
↑ Schmidt M, Scheulen ME, Dittrich C, Obrist P, Marschner N, Dirix L, et al. (February 2010). "An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer". Annals of Oncology. 21 (2): 275–82. doi: 10.1093/annonc/mdp314 . PMID 19633042.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] "Adecatumumab - Amgen/Merck Serono". Adis Insight. Springer Nature Switzerland AG.

[pmid16930989-2] Oberneder R, Weckermann D, Ebner B, Quadt C, Kirchinger P, Raum T, et al. (October 2006). "A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients". European Journal of Cancer. 42 (15): 2530–8. doi:10.1016/j.ejca.2006.05.029. PMID 16930989.

[pmid15655555-3] Prang N, Preithner S, Brischwein K, Göster P, Wöppel A, Müller J, et al. (January 2005). "Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines". British Journal of Cancer. 92 (2): 342–9. doi:10.1038/sj.bjc.6602310. PMC 2361858 . PMID 15655555.

[4] Schmidt M, Scheulen ME, Dittrich C, Obrist P, Marschner N, Dirix L, et al. (February 2010). "An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer". Annals of Oncology. 21 (2): 275–82. doi: 10.1093/annonc/mdp314 . PMID 19633042.

[1]

[2]

[3]

[4]